Lisa Pickering

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6022457/publications.pdf

Version: 2024-02-01

22 papers 9,682 citations

623188 14 h-index ⁷⁹⁴¹⁴¹
19
g-index

24 all docs

24 docs citations

times ranked

24

16623 citing authors

#	Article	IF	CITATIONS
1	Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. New England Journal of Medicine, 2012, 366, 883-892.	13.9	6,769
2	Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nature Genetics, 2014, 46, 225-233.	9.4	1,103
3	Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell, 2018, 173, 581-594.e12.	13.5	609
4	Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell, 2018, 173, 595-610.e11.	13.5	472
5	Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. European Urology, 2014, 66, 936-948.	0.9	141
6	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1305-1320.	5.7	123
7	Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nature Communications, 2015, 6, 6336.	5.8	100
8	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1321-1337.	5.7	66
9	Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. Lancet, The, 2022, 399, 905-907.	6.3	60
10	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. Cell Reports, 2020, 31, 107550.	2.9	51
11	Selection of metastasis competent subclones in the tumour interior. Nature Ecology and Evolution, 2021, 5, 1033-1045.	3.4	50
12	Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer. Cancer Cell, 2022, 40, 114-116.	7.7	50
13	Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. Nature Ecology and Evolution, 2022, 6, 88-102.	3.4	30
14	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel GroupÂstudy. European Journal of Cancer, 2017, 80, 55-62.	1.3	18
15	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 3317-3328.	3.2	14
16	Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients. Translational Oncology, 2017, 10, 679-685.	1.7	9
17	Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877742.	1.4	7
18	Pazopanib-Induced Alopecia, an Underestimated Toxicity?. Frontiers in Oncology, 2015, 5, 112.	1.3	4

#	Article	lF	CITATIONS
19	Longitudinal cohort analysis of patients with metastatic penile cancer treated in a large quaternary academic centre. Journal of Clinical Urology, 2023, 16, 293-302.	0.1	2
20	Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. Expert Review of Anticancer Therapy, 2020, 20, 343-354.	1.1	0
21	Abstract A012: Advanced melanoma exhibits a diversity of evolutionary routes to lethality. Cancer Research, 2022, 82, A012-A012.	0.4	O
22	Abstract PR002: Advanced melanoma exhibits a diversity of evolutionary routes to lethality. Cancer Research, 2022, 82, PR002-PR002.	0.4	0